Navigation Links
Interleukin Genetics Retains Top Life Science Communications Firms
Date:3/18/2008

Stern Investor Relations and LaVoie Group Selected as IR, PR Agencies of

Record

WALTHAM, Mass., March 18 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc., (Amex: ILI), announced today that it has retained two premier life science communications firms, Stern Investor Relations, Inc., and LaVoie Group, as agencies of record to provide investor relations and public relations services, respectively.

The two firms will provide strategic counsel and execution, will lead efforts to communicate Interleukin Genetics' vision to use the science of applied genetics to personalize health management and will support the Company's strategy to establish additional partnerships and relationships with biotechnology and pharmaceutical companies.

Lewis H. Bender, Chief Executive Officer commented, "Interleukin Genetics has a strong message on the value of diagnostic testing to empower consumers to personalize their health. With the addition of these two firms, I am confident that we will deliver our message more effectively to our key constituencies."

About LaVoie Group

LaVoie Group provides strategic, integrated marketing and communications- including marketing strategy, corporate communications, as well as public and investor relations to life sciences and healthcare companies. LaVoie Group's clients range from start-ups to industry leaders. For more information, visit http://www.lavoiegroup.com.

About Stern Investor Relations

Stern Investor Relations provides investor relations consulting services to biotechnology and healthcare companies. Stern IR develops and implements strategic investor relations programs designed to effectively manage communications with the investment community. Founded in 1998, Stern IR offers a full range of investor relations services. For more information, please visit http://www.sternir.com.

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. The Company currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers. Interleukin is headquartered in Waltham, MA. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward- looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2006 as amended, filed with the Securities and Exchange Commission, our quarterly reports on Form 10- Q and other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
2. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
3. Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results
4. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
5. Interleukin Genetics Announces Management and Board Appointments
6. deCODE genetics to Webcast Presentation at Lehman Brothers Eleventh Annual Global Healthcare Conference
7. deCODE Genetics Announces Full-year 2007 Financial Results
8. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
9. CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases
10. deCODE genetics to Webcast Presentation at BIO CEO and Investor Conference
11. Smart Genetics Announces Plans to Launch a New Alzheimers Risk Assessment Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
Breaking Biology Technology:
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):